Willow Biosciences, Inc. is a biotechnology company, which engages in the research, development, and commercialization of plant derived ingredients for consumer care, food and beverage, and pharmaceutical products. The company is headquartered in Calgary, Alberta and currently employs 19 full-time employees. The company went IPO on 2017-09-14. The firm develops and produces precision fermented functional ingredients for the health and wellness, food and beverage and personal care markets. Its FutureGrown biotechnology platform allows production with sustainability at its core. Its commercial product, Cannabigerol CBG, which is a cannabinoid that has anti-microbial, anti-inflammatory, and antioxidant properties. The company also offers BioOxi, a bio-oxidation technology platform. By leveraging BioOxi, commercial partners can revolutionize manufacturing of oxygenated and hydroxylated functional ingredients, such as steroids, polyphenols, oxyterpenes and certain other targeted ingredients produced from such methods. The company is also developing BioOxi-based process for production of the generic active pharmaceutical ingredient (API), hydrocortisone, and its derivatives. Its other pipeline products include Ursodeoxycholic acid (UCAC), Astaxanthin, B-carotene and others.